FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer By Ogkologos - July 15, 2026 51 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength Could Functional Precision Medicine Be the New Precision Oncology? Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord November 10, 2022 How Breast Cancer Risk Assessment Tools Work June 27, 2024 Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy July 13, 2020 Study Probes Awareness of Alcohol’s Link to Cancer January 18, 2023 Load more HOT NEWS Woman with Breast Cancer May Have Saved Her Twin’s Life by... Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment... Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term...
